Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma.
BloodSep 3, 2026
Clinical ResearchOncology (Medical)
Susan Bal, Myo Htut, Omar Nadeem et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 1 multicenter trial evaluated arlocabtagene autoleucel (arlo-cel), a CAR T-cell therapy targeting GPRC5D, in 84 adults with heavily pretreated relapsed/refractory multiple myeloma. The study found an overall response rate of 87%, with a complete response rate of 53% and a median progression-free survival of 18.3 months.
Key findings
- Overall response rate was 87%, with a complete response rate of 53%.
- Median progression-free survival was 18.3 months (95% CI, 11.8-21.9).
- One-year overall survival rate was 90%.
- Cytokine release syndrome occurred in 82% of patients, mostly grade 1/2.
Why it matters
The study highlights the potential of arlocabtagene autoleucel as a promising treatment option for patients with relapsed/refractory multiple myeloma, a population with limited therapeutic alternatives. The high response rates and manageable safety profile warrant further investigation.